Fig 1.
PRISMA flow chart describing the study selection process.
Table 1.
Studies included in review and meta-analysis.
Fig 2.
Forest plot of HIV prevalence in trans feminine individuals compared to all adults (age 15+).
The scale on the x-axis is log odds ratio. The percentages indicate the weight of each country by year within the meta-analysis. The numbers in the right column are the log odds ratios including their confidence intervals. We converted these log odds ratios into odds ratios, as described in Table 2.
Fig 3.
Forest plot of HIV prevalence in trans masculine individuals compared to all adults (age 15+).
The scale on the x-axis is log odds ratio. The percentages indicate the weight of each country by year within the meta-analysis. The numbers in the right column are the log odds ratios including their confidence intervals. We converted these log odds ratios into odds ratios, as described in Table 3.
Table 2.
Meta-analysis of HIV prevalence in trans feminine individuals compared to all adults (age 15+).
Table 3.
Meta-analysis of HIV prevalence in trans masculine individuals compared to all adults (age 15+).
Table 4.
HIV prevalence and odds ratios for trans feminine individuals compared to all adults (age 15+), separated by geographic region.
Table 5.
HIV prevalence in trans feminine individuals, separated by sampling method.
Fig 4.
Forest plot of HIV prevalence in trans feminine individuals in the USA compared to all adults (age 15+) in the USA.
The 10 country-year including 18 studies above the line are studies where data were collected prior to the introduction of PrEP (2012). The 3 country-year including 6 studies below the line are studies where data were collected after the introduction of PrEP. The scale on the x-axis is log odds ratio. The percentages indicate the weight of each sample within the meta-analysis. The numbers in the right column are the log odds ratios including their confidence intervals.
Table 6.
HIV prevalence and odds ratios for trans feminine individuals compared to all adults (age 15+) in US-based studies, according to whether data was collected before or after the introduction of PrEP (2012).